Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28658741 | 0.99 | CA1 (0.43) | CA1CA2CA7CA9CA14 | |
| Hydrochloric Acid SCHEMBL8298614 | 0.99 | CA1 (0.43) | CA1CA2CA7CA9CA14 | |
| Bromide SCHEMBL30920113 | 0.99 | CA1 (0.43) | CA1CA2CA7CA9CA14 | |
| SCHEMBL4478957 | 0.91 | NQO2 (0.41) | CA1CA2CA7CA9CA14 | |
| SCHEMBL19960840 | 0.86 | ALDH1A1 (0.40) | CA1CA2CA7CA9CA14 | |
| SCHEMBL7124159 | 0.85 | CA1 (0.46) | CA1CA2CA7CA9CA14 | |
| SCHEMBL10516146 | 0.85 | KMT2A (0.48) | CA1CA2CA7CA9CA14 | |
| Hydrochloric Acid SCHEMBL19953589 | 0.85 | TSHR (0.41) | CA1CA2CA7CA9CA14 | |
| Hydrochloric Acid SCHEMBL3534709 | 0.84 | CA1 (0.45) | CA1CA2CA7CA9CA14 | |
| SCHEMBL23119015 | 0.82 | TSHR (0.60) | TSHRNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | SHANGHAI LITEDD CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2021228216-A1 | BIARYL COMPOUND CAPABLE OF SERVING AS RORγ MODULATOR | 上海辉启生物医药科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-1869001-B1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| WO-2006102998-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (DE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | RORC, RORB, RORA | CA1 1641/4885CA2 1884/4885CA7 1211/4885 |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | RORB, RORA, RORC | CA1 1999/4885CA2 2517/4885CA7 1652/4885 |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | CA1 1120/4885CA2 573/4885CA7 532/4885 |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | CA1 492/4885CA2 575/4885CA7 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.